Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists

Published on Mar 24, 2016in Thrombosis and Haemostasis4.733
· DOI :10.1160/TH15-11-0892
Marjolein P. A. Brekelmans9
Estimated H-index: 9
(UvA: University of Amsterdam),
S.M. Bleker4
Estimated H-index: 4
(UvA: University of Amsterdam)
+ 10 AuthorsAlexander T. Cohen22
Estimated H-index: 22
(Guy's and St Thomas' NHS Foundation Trust)
Edoxaban is a once-daily direct oral anticoagulant (DOAC). The Hokusai-VTE study revealed that, after initial treatment with heparin, edoxaban was non-inferior to and safer than vitamin K antagonists (VKA) in the prevention of recurrent deep-vein thrombosis and pulmonary embolism. This is the first report on the clinical relevance and management of bleeding events with edoxaban. All major bleeding events were classified blindly by three study-independent adjudicators. Pre-defined criteria were used to classify severity of clinical presentation and, separately, the clinical course and outcome into four categories. Major bleeding occurred in 56 patients treated with edoxaban and 65 patients treated with VKA. The severest categories (3 or 4) of the clinical presentation were assigned to 46 % of the major bleeding episodes in edoxaban recipients versus 58 % of the major bleeds in VKA recipients (odds ratio [OR] 0.62, 95 % confidence interval [CI] 0.30–1.27, p = 0.19). Clinical course was classified as severe (category 3 or 4) in 23 % of the edoxaban and 29 % of the VKA associated bleeds (OR 0.73, 95 % CI 0.32–1.66, p = 0.46). In conclusion, edoxaban associated major bleeding events have a comparable clinical presentation and course to major bleeds with VKA in patients treated for venous thromboembolism in the Hokusai-VTE study. These results may assure physicians that it is safe to prescribe this medication. If a major bleeding during edoxaban treatment occurs, its clinical presentation and clinical course are not worse than in VKA-treated patients.
  • References (23)
  • Citations (9)
📖 Papers frequently viewed together
30 Citations
27 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
27 CitationsSource
#1Mathias Johansen (Copenhagen University Hospital)H-Index: 4
#2Anne Wareing (UCPH: University of Copenhagen)H-Index: 10
Last. Arash Afshari (Copenhagen University Hospital)H-Index: 19
view all 5 authors...
Background Treatment with vitamin K antagonists is associated with increased morbidity and mortality. Reversal therapy with prothrombin complex concentrate (PCC) is used increasingly and is recommended in the treatment of patients with bleeding complications undertaking surgical interventions, as well as patients at high risk of bleeding. Evidence is lacking regarding indication, dosing, efficacy and safety. Objectives We assessed the benefits and harms of PCC compared with fresh frozen plasma i...
20 CitationsSource
#1David J. Graham (CDER: Center for Drug Evaluation and Research)H-Index: 32
#2Marsha E. Reichman (CDER: Center for Drug Evaluation and Research)H-Index: 11
Last. Jeffrey A. Kelman (Centers for Medicare and Medicaid Services)H-Index: 17
view all 13 authors...
Background— The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established. Methods and Results— We formed new-user cohorts of propensity score–matched elderly patients enrolled in Medicare who initiated dabigatran or warfarin for treatment of nonvalvular atrial fibrillation between October 2010 and December 2012. Among 134 414 patients with 37 587 person-years of follow-up, there were 2715 primary outco...
400 CitationsSource
#1Nick van EsH-Index: 17
#2Michiel CoppensH-Index: 22
Last. Harry R. BüllerH-Index: 92
view all 5 authors...
In the last 4 years, 6 phase 3 trials including a total of 27 023 patients with venous thromboembolism (VTE) compared a direct oral anticoagulant (DOAC) with vitamin K antagonists (VKAs). To aid the clinician in assessing the amount of information, we address frequently raised clinical questions in a review of combined trial results. We included the phase 3 trials that compared dabigatran etexilate, rivaroxaban, apixaban, or edoxaban with VKA therapy in patients with acute symptomatic VTE. Recur...
290 CitationsSource
#1T. van der Hulle (LUMC: Leiden University Medical Center)H-Index: 10
#2Judith Kooiman (LUMC: Leiden University Medical Center)H-Index: 17
Last. Menno V. Huisman (LUMC: Leiden University Medical Center)H-Index: 61
view all 6 authors...
SummaryIntroduction New direct oral anticoagulants (NOACs) constitute a novel treatment option for acute venous thromboembolism (VTE), with practical advantages. Individual studies have demonstrated comparable efficacy to that of vitamin K antagonists (VKAs) and have suggested a more favorable safety profile . We performed a meta-analysis to determine the efficacy and safety of NOACs as compared with those of VKAs in patients with acute VTE. Methods We searched MEDLINE, EMBASE, the Cochrane Data...
240 CitationsSource
#1Harry R. BüllerH-Index: 92
#2Hervé DecoususH-Index: 38
Last. Phil WellsH-Index: 5
view all 11 authors...
Methods In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolis...
930 CitationsSource
#1Giancarlo A (University of Perugia)H-Index: 75
#2Harry R. BüllerH-Index: 92
Last. Jeffrey I. WeitzH-Index: 90
view all 11 authors...
METHODS In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relev...
1,049 CitationsSource
#1Gary E. Raskob (OU: University of Oklahoma)H-Index: 73
#2H. R. BüllerH-Index: 46
Last. Michele Mercuri (Daiichi Sankyo)H-Index: 26
view all 8 authors...
New oral anticoagulants may simplify long-term therapy by eliminating the need for laboratory monitoring. Edoxaban is an oral, direct inhibitor of factor Xa that is given in a fixed dose once daily. The Hokusai-VTE study is a randomized, double-blind trial to evaluate whether initial low molecular weight heparin (LMWH) followed by edoxaban (60 mg once daily) is non-inferior to LMWH followed by warfarin (International Normalized Ratio of 2.0-3.0) for the prevention of recurrent thromboembolism in...
58 CitationsSource
#1Scott Kaatz (Hurley Medical Center)H-Index: 33
#2Mark A. Crowther (HHS: Hamilton Health Sciences)H-Index: 93
The target-specific oral anticoagulants represent the first new oral anti-thrombotic therapy in over 50 years and have the potential to make therapy easier and hence more accessible to many patients. Like any new therapy, the potential benefits must be weighed against the potential challenges and one of the most concerning aspects of the new target-specific oral anticoagulants is the lack of a proven method to reverse their effect. Unlike the vitamin K antagonist, i.e. warfarin, there is no spec...
33 CitationsSource
#1Hein Heidbuchel (Katholieke Universiteit Leuven)H-Index: 66
#2Peter Verhamme (Katholieke Universiteit Leuven)H-Index: 17
Last. Paulus Kirchhof (WWU: University of Münster)H-Index: 87
view all 9 authors...
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients will have to learn how to use these drugs effectively and safely in clinical practice. Many unresolved questions on how to optimally use these drugs in specific clinical situations remain. The European Heart Rhythm Association set out to coordinate a unified way of informing physicians on the use of the differen...
571 CitationsSource
Cited By9
#1Eduardo Ramacciotti (Loyola University Medical Center)H-Index: 15
Last. Jawed Fareed (Loyola University Medical Center)H-Index: 49
view all 6 authors...
Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to the previously approved DOACs. This review summarizes the main properties of edoxaban, the outcomes results of its pivotal global clinical trials and the peculiar clinical features of this compound. ...
#1Luuk J. J. Scheres (LUMC: Leiden University Medical Center)H-Index: 5
Last. A. DellucH-Index: 2
view all 13 authors...
OBJECTIVE: To investigate the characteristics and outcome of abnormal vaginal bleeding in women receiving edoxaban or warfarin for treatment of venous thromboembolism (VTE). DESIGN AND SETTING: Post hoc analysis of the Hokusai-VTE study, a multicentre, randomised, double-blind trial comparing edoxaban with warfarin for acute symptomatic VTE. POPULATION: Women below 50 years receiving edoxaban or warfarin for treatment of VTE. METHODS: We collected data on diagnostic measures, treatment, and clin...
5 CitationsSource
#2Rahat A. Abdoellakhan (UMCG: University Medical Center Groningen)H-Index: 3
Last. Michiel CoppensH-Index: 22
view all 11 authors...
Essentials Data on clinical outcome of vitamin K antagonist (VKA)-associated bleeds are scarce. Cohort study of patients with VKA bleeds treated with prothrombin complex concentrate (PCC). Effective haemostasis was achieved in 68% of patients with a VKA-associated bleeding. Thromboembolism rates were low and mortality rates high at 30 days after PCC administration. Background Vitamin K antagonists (VKA) are used for the treatment of thromboembolism. Patients with severe VKA-associated bleeding r...
2 CitationsSource
#1Noémie KraaijpoelH-Index: 6
#2Nick van EsH-Index: 17
Last. Harry R. BüllerH-Index: 92
view all 9 authors...
Cancer patients with venous thromboembolism (VTE) have a two- to six-fold increased risk of anticoagulant-related major bleeding events compared with VTE patients without cancer. It is unknown whether major bleeding events are more severe in cancer patients than in those without cancer. Individual patient data from four randomized phase III trials that compared factor Xa inhibitors and vitamin K antagonists for the treatment of VTE were used to compare the severity of major bleeding events in pa...
3 CitationsSource
Factor Xa (fXa)-inhibitors are as effective and safer than vitamin-K–antagonists (VKA) in the treatment of venous thromboembolism (VTE). We previously classified the severity of clinical presentation and course of all major bleeding events from the EINSTEIN, AMPLIFY and HOKUSAI-VTE trials separately. The current aim was to combine these findings in order to increase precision, assess a class effect and analyse presentation and course for different types of bleeding, i. e. intracranial, gastro-in...
9 CitationsSource
#1Gregory Y.H. LipH-Index: 141
#2Ben Freedman (USYD: University of Sydney)H-Index: 14
Last. Tatjana S. Potpara (University of Belgrade)H-Index: 26
view all 4 authors...
Concepts and our approaches to stroke prevention in atrial fibrillation (AF) have changed markedly over the last decade. There has been an evolution over the approach to stroke and bleeding risk assessment, as well as new treatment options. An increasing awareness of AF has led to calls to improve the detection of and population screening for AF. Stroke and bleeding risk assessment continues to evolve, and the ongoing debate on balance between simplicity and practicality, against precision medic...
138 CitationsSource
#1Sam Schulman (KI: Karolinska Institutet)H-Index: 64
#2Bruce Ritchie (U of A: University of Alberta)H-Index: 23
Last. Michelle Zondag (McMaster University)H-Index: 6
view all 8 authors...
Abstract The reversal of dabigatran-associated major bleeding can now be achieved with the antidote idarucizumab. We evaluated activated prothrombin complex concentrate (aPCC) as an alternative for this purpose. Patients treated with dabigatran and suffering a major bleed were treated as per existing hospital protocol with aPCC. They were subsequently recruited for a 30-day follow-up. Effectiveness was evaluated by the treating physician, using an Assessment Guide. Safety outcomes were arterial ...
17 CitationsSource
#1Stefano Barco (University of Mainz)H-Index: 8
#2Stavros Konstantinides (DUTH: Democritus University of Thrace)H-Index: 48
ABSTRACT The presence and severity of right ventricular (RV) dysfunction is a key determinant of prognosis in the acute phase of pulmonary embolism (PE). Risk-adapted treatment strategies continue to evolve, tailoring initial management to the clinical presentation and the functional status of the RV. Beyond pharmacological and, if necessary, mechanical circulatory support, systemic thrombolysis remains the mainstay of treatment for hemodynamically unstable patients; in contrast, it is not routi...
8 CitationsSource
#1Suzanne M. BlekerH-Index: 9
#2Alex S. CohenH-Index: 56
Last. S. MidddeldorpH-Index: 47
view all 10 authors...
Apixaban, a direct acting oral anticoagulant (DOAC), was found to be non-inferior to and safer as enoxaparin followed by warfarin for treatment of venous thromboembolism (VTE) in the AMPLIFY trial. Information is needed on how bleeding events with DOACs present and develop. In this post-hoc analysis, the clinical presentation and course of all major and clinically relevant non major (CRNM) bleeding events in the AMPLIFY trial were blindly classified by three investigators, using pre-designed cla...
7 CitationsSource